The investment will fund new innovations, commercial partnerships, and clinical adoption. The company's vision is to accelerate clinical adoption of the company's Tapestri Platform across multiple cancer segments by providing crucial insights into treatment decision-making. This effort will be supported by the broadening of the platform's single-cell tri-omics capabilities, which recently added targeted gene expression analysis to genotype analysis in a single assay.

Mission Bio is the single-cell tri-omics leader. The company's Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies.